Abstract
Monosomy 7 [−7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with −7/del(7q) as isolated cytogenetic abnormality (86 with del(7q) and 194 with −7). Patients with del(7q) or −7 had similar demographic and disease-related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in −7 and 73% in del(7q) group). Median number of mutations per patient was 2 (range 0–8). There was no difference in mutation frequency between the two groups. Patients harbouring ≥2 mutations had a worse outcome than patients with <2 or no mutations (leukaemic transformation at 24 months, 38% and 20%, respectively, p = 0.044). Untreated patients with del(7q) had better overall survival (OS) compared with −7 (median OS, 34 vs 17 months, p = 0.034). In multivariable analysis, blast count, TP53 mutations and number of mutations were independent predictors of OS, whereas the cytogenetic subgroups did not retain prognostic relevance. This study highlights the importance of mutational analysis in terms of prognosis in MDS patients with isolated −7 or del(7q).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol. 1996;33:127–38. http://www.ncbi.nlm.nih.gov/pubmed/8722683.
Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol. 1996;94:116–9. http://www.ncbi.nlm.nih.gov/pubmed/8757518.
Pasquali F, Bernasconi P, Casalone R, Fraccaro M, Bernasconi C, Lazzarino M, et al. Pathogenetic significance of “pure” monosomy 7 in myeloproliferative disorders. Analysis of 14 cases. Hum Genet. 1982;62:40–51. http://www.ncbi.nlm.nih.gov/pubmed/6961098.
Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol. 1994;46:270–7. http://www.ncbi.nlm.nih.gov/pubmed/8037176.
Velloso ER, Michaux L, Ferrant A, Hernandez JM, Meeus P, Dierlamm J. et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. Br J Haematol.1996;92:574–81. http://www.ncbi.nlm.nih.gov/pubmed/8616020.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88. http://www.ncbi.nlm.nih.gov/pubmed/9058730.
Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer. 2012;118:127–33. http://www.ncbi.nlm.nih.gov/pubmed/21717439.
Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9. http://jco.ascopubs.org.offcampus.dam.unito.it/content/30/8/820.full.
Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113:3331–40. http://www.ncbi.nlm.nih.gov/pubmed/18988232.
Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012;119:6109–17. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3383019&tool=pmcentrez&rendertype=abstract.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. http://bloodjournal.hematologylibrary.org.offcampus.dam.unito.it/content/120/12/2454.long.
Döhner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood. 1998;92:4031–5. http://www.ncbi.nlm.nih.gov/pubmed/9834205.
Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930–5. http://www.ncbi.nlm.nih.gov/pubmed/8822909.
Asou H, Matsui H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, et al. Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun. 2009;383:245–51. http://www.ncbi.nlm.nih.gov/pubmed/19358830.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722–6. http://www.ncbi.nlm.nih.gov/pubmed/20601953.
Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24:1799–804. http://www.nature.com.offcampus.dam.unito.it/leu/journal/v24/n10/full/leu2010167a.html.
Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tönnissen ERLTM, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42:665–7. http://www.ncbi.nlm.nih.gov/pubmed/20601954.
Nagamachi A, Matsui H, Asou H, Ozaki Y, Aki D, Kanai A, et al. Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell. 2013;24:305–17. http://www.ncbi.nlm.nih.gov/pubmed/24029230.
Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014;25:652–65. http://www.ncbi.nlm.nih.gov/pubmed/24794707.
Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem. 2011;286:25211–23. http://www.ncbi.nlm.nih.gov/pubmed/21532034.
Inaba T, Honda H, Matsui H. The enigma of monosomy 7. Blood. 2018;131:2891–8. http://www.ncbi.nlm.nih.gov/pubmed/29615405.
Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, et al. Recurrent genetic defects on chromosome 7q in myeloid neoplasms. Leukemia. 2014;28:1348–51. http://www.ncbi.nlm.nih.gov/pubmed/24429498.
Wong JCY, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, et al. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood. 2010;115:4524–32. http://www.ncbi.nlm.nih.gov/pubmed/20233966.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. http://bloodjournal.hematologylibrary.org/content/114/5/937.full.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32. http://www.ncbi.nlm.nih.gov/pubmed/16079113.
Bono E, McLornan D, Travaglino E, Gandhi S, Gallì A, Khan AA, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33:2495–505. http://www.ncbi.nlm.nih.gov/pubmed/30940907.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.
Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC, et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica. 2013;98:1058-1066. http://www.haematologica.org/content/98/7/1058.long.
Marisavljevic D, Cemerikic V, Rolovic Z, Boskovic D, Colovic M. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2005;22:169–75. http://www.ncbi.nlm.nih.gov/pubmed/15965280.
Huang T-C, Ko B-S, Tang J-L, Hsu C, Chen C-Y, Tsay W, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia. 2008;22:544–50. http://www.ncbi.nlm.nih.gov/pubmed/18094713.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506. https://doi.org/10.1056/NEJMoa1013343.
Jung S-H, Kim Y-J, Yim S-H, Kim H-J, Kwon Y-R, Hur E-H, et al. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016;7:55264–75. http://www.ncbi.nlm.nih.gov/pubmed/27419369.
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27. http://bloodjournal.hematologylibrary.org/content/122/22/3616.long?sso-checked=1.quiz3699.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7. http://www.ncbi.nlm.nih.gov/pubmed/24220272.
Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia. 2005;19:1424–31. http://www.nature.com.offcampus.dam.unito.it/leu/journal/v19/n8/full/2403806a.html.
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472-8.
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–9. http://jco.ascopubs.org.offcampus.dam.unito.it/content/28/4/562.full.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018;9:9714–27. http://www.oncotarget.com/fulltext/23882.
Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754–62. http://jco.ascopubs.org/content/27/5/754.abstract?ijkey=b1fbbc2d4d064656b27b5da1a506032a8fa0e190&keytype2=tf_ipsecsha.
Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47. https://doi.org/10.1056/NEJMoa1611604.
Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021–34. http://bloodjournal.hematologylibrary.org/content/122/25/4021.full.
Steensma DP. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Blood. 2018;132:1657–63. http://www.bloodjournal.org/content/132/22/2419.2.long?sso-checked=true.
Funding
This work was supported in part by a grant from the Instituto de Salud Carlos III, Ministerio de Economia y Competividad, Spain (PI/14/00013; PI/17/0575); 2017 SGR288 (GRC) Generalitat de Catalunya; economical support from CERCA Programme/Generalitat de Catalunya, Fundació Internacional Josep Carreras and from Celgene International. The research leading to this invention has received funding from ‘la Caixa’ Foundation.
Author information
Authors and Affiliations
Contributions
GJM designed the study and provided funding for the research; EC and AGK performed the research and the statistical analysis; EC and AGK collected data, analyzed data and wrote the paper; EC, AGK, VA, ES, JS, DH, SB, SAM, AK, JC, NL, DF, UG, ABVM, GFS, FS, GJM and VS collected data and treated patients; KS and BH performed the cytogenetic analysis; SB, SAM, NL and AK contributed to the study experiments; DH, VS, GFS, FS and GJM commented on the paper; all the authors reviewed and approved the paper.
Corresponding author
Ethics declarations
Conflict of interest
EC, AGK, VA, ES, JS, DH, KS, SB, SAM, AK, JC, NL, DF, UG, BH, ABVM, FS and GJM have no conflict of interests; VS has received honoraria from honoraria da Celgene, Novartis, Takeda, Amgen, Astex and Janssen; GFS has received honoraria from and/or played an advisory role for AbbVie, Amgen, Böehringer-Ingelheim, Celgene, Helsinn Healthcare and Hoffmann—La Roche, Janssen—Cilag and Novartis. GFS and ES work at Hospital Universitario y Politécnico La Fe, which receives research funding and/or participates in multiple clinical trials funded by different pharmaceutical companies, including AbbVie, Amgen, Böehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Helsinn Healthcare and Hoffman—La Roche, Janssen—Cilag, Novartis and Onconova. GFS is also a member of the Spanish Group on Myelodysplastic Syndromes (Grupo Español de Síndromes Mielodisplásicos, GESMD), which is sponsored by Celgene and Novartis.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Crisà, E., Kulasekararaj, A.G., Adema, V. et al. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia 34, 2441–2450 (2020). https://doi.org/10.1038/s41375-020-0728-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0728-x